Brief Report: Reassessment of bTMB as a Predictive Biomarker in NSCLC Immunotherapy—A Reanalysis of OAK and POPLAR
Jiaqian Liu, Na Bo, Patrick Nana-Sinkam, Ying Ding · 2026
Read Brief Report: Reassessment of bTMB as a Predictive Biomarker in NSCLC Immunotherapy—A Reanalysis of OAK and POPLAR by Jiaqian Liu, Na Bo, Patrick Nana-Sinkam, Ying Ding (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13675807.txt.
Description
Jiaqian Liu and co-authors re-check whether a blood-based mutation count can pick lung cancer patients who gain from immune therapy. Their 2026 reanalysis pools two past trials of advanced disease. Earlier work looked mainly at the high-count group, which can mislead.
About two hundred patients from one trial and five hundred eighty-three from the other had usable blood scores. Cut points from four to twenty-six were tested. High scorers gained more on time without growth in both trials. For overall survival, though, high and low groups looked alike in the larger trial. The authors conclude the marker predicts growth delay but not longer life. They warn that one-group trends alone cannot prove a marker's worth.
Catalog record
| CREATOR | Jiaqian Liu, Na Bo, Patrick Nana-Sinkam, Ying Ding |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |